Free Trial

Trevi Therapeutics (TRVI) Stock Forecast & Price Target

Trevi Therapeutics logo
$2.77 -0.23 (-7.67%)
(As of 11/20/2024 ET)

Trevi Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
9

Based on 9 Wall Street analysts who have issued ratings for Trevi Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 9 analysts, 7 have given a buy rating, and 2 have given a strong buy rating for TRVI.

Consensus Price Target

$7.43
168.18% Upside
According to the 9 analysts' twelve-month price targets for Trevi Therapeutics, the average price target is $7.43. The highest price target for TRVI is $9.00, while the lowest price target for TRVI is $6.00. The average price target represents a forecasted upside of 168.18% from the current price of $2.77.
Get the Latest News and Ratings for TRVI and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Trevi Therapeutics and its competitors.

Sign Up

TRVI Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$7.43$7.43$8.00$6.75
Forecasted Upside168.18% Upside129.99% Upside167.56% Upside492.11% Upside
Consensus Rating
Buy
Buy
Buy
Buy

TRVI Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TRVI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Trevi Therapeutics Stock vs. The Competition

TypeTrevi TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.22
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside168.18% Upside26,931.60% Upside9.83% Upside
News Sentiment Rating
Neutral News

See Recent TRVI News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/8/2024Needham & Company LLC
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00+175.86%
10/22/2024HC Wainwright
2 of 5 stars
O. Livnat
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00+79.10%
10/7/2024B. Riley
4 of 5 stars
 Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00+101.34%
9/9/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
F. Khurshid
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
9/9/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$6.00 ➝ $7.00+134.90%
8/30/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Deschner
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$9.00+209.28%
8/19/2024EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Kolbert
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/13/2024Rodman & Renshaw
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$7.00+146.48%
3/21/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$9.00+157.88%
3/14/2023Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$7.00+280.43%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:29 AM ET.


TRVI Forecast - Frequently Asked Questions

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Trevi Therapeutics is $7.43, with a high forecast of $9.00 and a low forecast of $6.00.

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last year. There are currently 7 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRVI shares.

According to analysts, Trevi Therapeutics's stock has a predicted upside of 168.18% based on their 12-month stock forecasts.

Over the previous 90 days, Trevi Therapeutics's stock had 1 upgrade by analysts.

Trevi Therapeutics has been rated by research analysts at B. Riley, HC Wainwright, Leerink Partners, Leerink Partnrs, Needham & Company LLC, and Raymond James in the past 90 days.

Analysts like Trevi Therapeutics more than other "medical" companies. The consensus rating for Trevi Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how TRVI compares to other companies.


This page (NASDAQ:TRVI) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners